

Marilyn Huang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4618994/publications.pdf>

Version: 2024-02-01

22
papers

298
citations

1307594

7
h-index

940533

16
g-index

23
all docs

23
docs citations

23
times ranked

290
citing authors

#	ARTICLE	IF	CITATIONS
1	Low-grade serous ovarian cancer: State of the science. <i>Gynecologic Oncology</i> , 2020, 156, 715-725.	1.4	74
2	Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 762-771.	1.6	71
3	Uterine rhabdomyosarcoma in adults. <i>Human Pathology</i> , 2018, 74, 122-128.	2.0	29
4	Identifying disparities in germline and somatic testing for ovarian cancer. <i>Gynecologic Oncology</i> , 2019, 153, 297-303.	1.4	25
5	Variation in type II endometrial cancer risk by Hispanic subpopulation: An exploratory analysis. <i>Gynecologic Oncology</i> , 2017, 147, 329-333.	1.4	15
6	Endometrial cancer from early to advanced-stage disease: an update for radiologists. <i>Abdominal Radiology</i> , 2021, 46, 5325-5336.	2.1	12
7	Impact of molecular testing in clinical practice in gynecologic cancers. <i>Cancer Medicine</i> , 2019, 8, 2013-2019.	2.8	11
8	A randomized phase II study of letrozole vs. observation in patients with newly diagnosed uterine leiomyosarcoma (uLMS). <i>Gynecologic Oncology Reports</i> , 2019, 27, 1-4.	0.6	10
9	The Vaginal Microbiome is Associated with Endometrial Cancer Grade and Histology. <i>Cancer Research Communications</i> , 2022, 2, 447-455.	1.7	8
10	Spontaneous tumor lysis syndrome occurring in untreated uterine cancer. <i>Gynecologic Oncology Reports</i> , 2017, 22, 40-42.	0.6	7
11	MOONSTONE/GOG-3032: Interim analysis of a phase 2 study of niraparib + dostarlimab in patients (pts) with platinum-resistant ovarian cancer (PROC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 5573-5573.	1.6	7
12	Lymphoepithelioma-Like Carcinoma of the Uterine Cervix. <i>American Journal of Clinical Pathology</i> , 2019, 151, 231-239.	0.7	6
13	Retreatment of chemotherapy-resistant metastatic choriocarcinoma with immunotherapy. <i>Gynecologic Oncology Reports</i> , 2022, 40, 100955.	0.6	6
14	mRNA expression in low grade serous ovarian cancer: Results of a nanoString assay in a diverse population. <i>Gynecologic Oncology</i> , 2020, 159, 554-562.	1.4	5
15	Lost opportunities for mismatch repair (MMR) screening among minority women with endometrial cancer. <i>Scientific Reports</i> , 2021, 11, 11712.	3.3	3
16	The Moore Criteria: Applicability in a diverse, non-trial, recurrent cervical cancer population. <i>Gynecologic Oncology</i> , 2020, 157, 167-172.	1.4	2
17	Assessment of Cancer Survivorship Training and Knowledge Among Resident Physicians in Obstetrics and Gynecology. <i>Journal of Cancer Education</i> , 2021, 36, 491-496.	1.3	2
18	Endometrial cancer among a cohort of urban Haitian immigrants. <i>World Journal of Clinical Oncology</i> , 2019, 10, 340-349.	2.3	2

#	ARTICLE	IF	CITATIONS
19	Management of placenta percreta in a Jehovahâ€™s Witness patient. <i>BMJ Case Reports</i> , 2018, 2018, bcr-2018-225260.	0.5	2
20	Preparation in the business and practice of medicine: perspectives from recent gynecologic oncology graduates and program directors. <i>Gynecologic Oncology Research and Practice</i> , 2017, 4, 14.	3.6	1
21	Effects of initiating physician-performed germline testing in safety net clinic patients with epithelial ovarian cancer. <i>Gynecologic Oncology Reports</i> , 2020, 34, 100662.	0.6	0
22	Factors Predicting Type II Histology in Endometrial Biopsies Among Postmenopausal Minority Women at a Safety-Net Hospital. <i>Journal of Women's Health</i> , 2021, 30, 1328-1333.	3.3	0